ASAH2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3712341	0.74	5/20
SCHEMBL3712342	0.74	5/20
SCHEMBL3712345	0.74	5/20
SCHEMBL3712347	0.74	5/20
Acetyl Ceramide (SCHEMBL58536)	0.71	2/20
Acetyl Ceramide (SCHEMBL1191825)	0.71	2/20
SCHEMBL358660	0.71	2/20
SCHEMBL504184	0.71	2/20
SCHEMBL560039	0.71	2/20
SCHEMBL760704	0.71	2/20
SCHEMBL2289536	0.71	2/20
SCHEMBL2734735	0.71	2/20
SCHEMBL4133165	0.71	2/20
SCHEMBL4133213	0.71	2/20
SCHEMBL2734386	0.69	2/20
SCHEMBL3016227	0.66	2/20
SCHEMBL486677	0.65	2/20
SCHEMBL1976275	0.65	2/20
SCHEMBL4133159	0.65	2/20
SCHEMBL4140908	0.65	2/20

Clinical trials — most relevant to ASAH2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.	PHASE4	COMPLETED
Bezafibrate Trial in CPT2 Deficiency	PHASE3	UNKNOWN
Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	PHASE2	UNKNOWN
Ambroxol as a Treatment for Parkinson's Disease Dementia	PHASE2	UNKNOWN
Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients	PHASE1	COMPLETED
Farber Disease Natural History Study	nan	COMPLETED
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease	nan	NOT_YET_RECRUITING
Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital	nan	NOT_YET_RECRUITING
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children	nan	NOT_YET_RECRUITING
Registry Gangliosidoses	nan	UNKNOWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Italian Anderson Fabry Disease Cardiovascular Registry	nan	RECRUITING
Miglustat on Gaucher Disease Type IIIB	nan	UNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Biomarkers Of Lung InVolvement In ASMD	nan	UNKNOWN
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
Ophthalmic Manifestations of Patients With Mucopolysaccharidosis	nan	UNKNOWN
Identification of Undiagnosed Lysosomal Acid Lipase Deficiency	nan	UNKNOWN
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Characterization of the Patient Population With Galactosialidosis	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Magnetic Resonance Spectroscopy in Acid Sphingomyelinase Deficiency	nan	UNKNOWN
The Natural History of Sialidosis Type I	nan	RECRUITING
Biomarker for Patients With Fabry Disease (BioFabry)	nan	WITHDRAWN
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders	nan	UNKNOWN
Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ASAH2 binder may also engage these)

Protein	Name	Similarity
Q91XT9	—	1.000	Q91XT9 →
Q29C43	—	0.999	Q29C43 →
Q5W7F1	—	0.998	Q5W7F1 →
Q9JHE3	—	0.998	Q9JHE3 →
Q0JL46	—	0.994	Q0JL46 →
F4HQM3	—	0.994	F4HQM3 →
Q304B9	—	0.993	Q304B9 →
Q54BK2	—	0.992	Q54BK2 →
Q9VA70	—	0.992	Q9VA70 →
F4KHQ8	—	0.991	F4KHQ8 →
Q55G11	—	0.987	Q55G11 →
Q9I596	—	0.981	Q9I596 →
Q9GV16	—	0.979	Q9GV16 →
GLB1	Beta-galactosidase	0.979	landscape →
P16098	—	0.978	P16098 →
Q60HF6	—	0.978	Q60HF6 →
O04931	—	0.978	O04931 →
D4AUF4	—	0.978	D4AUF4 →
MGAM2	Probable maltase-glucoamylase 2 (Maltase-gluc	0.978	landscape →
P0C7U1	—	0.978	P0C7U1 →
B3FWS5	—	0.978	B3FWS5 →
P82993	—	0.978	P82993 →
Q10916	—	0.977	Q10916 →
Q9SG80	—	0.977	Q9SG80 →
Q22915	—	0.977	Q22915 →
Q5R7P4	—	0.977	Q5R7P4 →
Q8L7W8	—	0.977	Q8L7W8 →
Q9LZV3	—	0.977	Q9LZV3 →
Q8WXQ8	—	0.977	Q8WXQ8 →
A0A348HAY2	—	0.977	A0A348HAY2 →